The EU AI Act is here: What it means for life sciences

The EU’s AI Act is finally here, representing the world’s most comprehensive set of regulations governing the use of artificial intelligence (AI). Life sciences companies at last gain clarity on what constitutes safe and responsible AI in the eyes of the law, the requirements for developing AI in the EU, the AI use cases that will be prohibited under the act and what penalties will befall companies that fail to comply.
 

While the law nominally applies only to AI systems and outputs developed and deployed inside the EU, we expect these regulations to become the de facto norm for the foreseeable future.
 

So what does it mean for life sciences companies? In this webinar, leaders from ZS’s pharma, medtech and digital connected health practices break down the Act, discussing:

• The Act’s key provisions as they pertain to life sciences, including the Act’s scope, penalties, timeline and categories of AI risk
• Implications for life sciences companies, including to risk management, data governance and transparency in AI development
• A set of recommendations for life sciences companies as they prepare for the Act to come into force